1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

AML - 1393

Automated Extraction of Adverse Events Reveals Relationship Between HMA/Ven Cycle Duration and Symptom Burden

John Lazar

Poster Presenter: John Lazar

Thumbnail for Avapritinib Treatment of Patients with Advanced Systemic Mastocytosis: 4-Year Safety, Effect on Bone and First-Line Efficacy Results of the PATHFINDER Clinical Study

MPN - 1037

Avapritinib Treatment of Patients with Advanced Systemic Mastocytosis: 4-Year Safety, Effect on Bone and First-Line Efficacy Results of the PATHFINDER Clinical Study

Michael Deininger

Poster Presenter: Michael Deininger

Thumbnail for Baseline Monocyte-Macrophage Exhaustion and NK-Cell Dysfunction Could Predict Response, Minimal Residual Disease, and Survival and Guide Treatment Choice in Newly Diagnosed Chronic Lymphocytic Leukemia Patients

CLL - 074

Baseline Monocyte-Macrophage Exhaustion and NK-Cell Dysfunction Could Predict Response, Minimal Residual Disease, and Survival and Guide Treatment Choice in Newly Diagnosed Chronic Lymphocytic Leukemia Patients

Omar Ali Elbaioumi

Poster Presenter: Omar Ali Elbaioumi

Thumbnail for Baseline Predictors of Survival and Spleen Response in Ruxolitinib-Treated Myelofibrosis: Development of the Ruxolitinib Prognostic Scoring System in a Real-World Cohort

MPN - 425

Baseline Predictors of Survival and Spleen Response in Ruxolitinib-Treated Myelofibrosis: Development of the Ruxolitinib Prognostic Scoring System in a Real-World Cohort

Alessandro Lagan?

Poster Presenter: Alessandro Lagan?

Thumbnail for Baseline Protein-Energy Malnutrition Identifies a High-Risk Phenotype in HMA-Treated Myelodysplastic Syndromes: A Propensity-Matched Real-World Analysis

MDS - 1284

Baseline Protein-Energy Malnutrition Identifies a High-Risk Phenotype in HMA-Treated Myelodysplastic Syndromes: A Propensity-Matched Real-World Analysis

Sooraj Srirangadhamu Gopu

Poster Presenter: Sooraj Srirangadhamu Gopu

MM - 386

Baseline Risk Modifiers for Multiple Myeloma Following Herpes Zoster: A Multicenter Retrospective Cohort Study

Aditya Anand

Poster Presenter: Aditya Anand

$Thumbnail for Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial$

MM - 1168

Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial

Robert Rifkin

Poster Presenter: Robert Rifkin

Video

$Thumbnail for Belantamab Mafodotin Combinations in Relapsed or Refractory Multiple Myeloma: Re-emergence of BCMA Antibody-Drug Conjugate Therapy Across Clinical Trials$

MM - 1622

Belantamab Mafodotin Combinations in Relapsed or Refractory Multiple Myeloma: Re-emergence of BCMA Antibody-Drug Conjugate Therapy Across Clinical Trials

Sri Pranita Cherukuri

Poster Presenter: Sri Pranita Cherukuri

$Thumbnail for Belantamab Mafodotin Triplets Versus Active-Control Triplets in Relapsed or Refractory Multiple Myeloma$

MM - 1277

Belantamab Mafodotin Triplets Versus Active-Control Triplets in Relapsed or Refractory Multiple Myeloma

Vasu Malhotra

Poster Presenter: Vasu Malhotra